Centrum 7/6  banner

Dr. Patrizia Cavazzoni

FDA approves Aduhelm to treat Alzheimer’s

FDA approves Aduhelm to treat Alzheimer’s

WASHINGTON – The  U.S. Food and Drug Administration announced Monday that it has approved Aduhelm (aducanumab) for the treatment of Alzheimer’s, the debilitating disease affecting 6.2 million Americans. Aduhelm was approved using the accelerated approval pathway, which can be used for a drug for a serious or life-threatening illness that provides a meaningful therapeutic advantage

PP_1170x120_10-25-21